18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
Recruiting
Phase 4
Interventional Study
Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant
Metastatic Prostate Cancer
Male Urogenital Diseases
Prostatic Diseases
Urogenital Diseases, Male
Genital Diseases, Male
Neoplasms
Neoplasms by Site
Urogenital Neoplasms
Genital Neoplasms, Male
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Male
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 15 (estimated)
- Sponsor
- VA Greater Los Angeles Healthcare System · Federal
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA RLT) at the West Los Angeles VA (WLA-VA) will be imaged with a baseline F-18 fluorodeoxyglucose positron emission tomography/computed tomography 18F-FDG PET/CT and a 18F-DCFP…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with mCRPC scheduled to undergo LuPSMA RLT.
* Willingness to undergo multiple serial PET/CT scans pre- and post-LuPSMA RLT.
* Ability of providing written informed consent.
Exclusion Criteria:
* Less than 18 years-old at the time of radiopharmaceutical administratio…
Contacts